Tristan J. Huie

Tristan J. Huie

Auto-generated profile, based on publicly available information

Tristan J. Huie

University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine; National Jewish Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
EPEvans R Fernández Peréz
Evans R Fernández Peréz
DSDavid B. Sprunger
David B. Sprunger
PRPailin Ratanawatkul
Pailin Ratanawatkul
Lisa MaierLisa Maier
Lisa Maier
THTristan J. Huie
Tristan J. Huie
KBKevin K. Brown
Kevin K. Brown

16 October 2023 in Chest
Verified
Journal Article
Closed access
MNMelissa L. New
Melissa L. New
TATimothy Amass
Timothy Amass
ANAnna Neumeier
Anna Neumeier
THTristan J. Huie
Tristan J. Huie

22 April 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
EPEvans R Fernández Peréz
Evans R Fernández Peréz
JCJames Crooks
James Crooks
JSJeffrey J. Swigris
Jeffrey J. Swigris
JSJoshua J. Solomon
Joshua J. Solomon
MMMichael P. Mohning
Michael P. Mohning
KFKaitlin Fier
Kaitlin Fier
Hypersensitivity pneumonitis (HP) is an immunologically mediated form of lung disease resulting from inhalational exposure to any of a large variety of antigens. A subgroup of patients with HP develops pulmonary fibrosis (fibrotic HP; FHP), a significant cause of morbidity and mortality. This study will evaluate the safety and efficacy of the antifibrotic pirfenidone in treating FHP.This single-centre, randomised, double-blind, placebo-controlled trial is enrolling adults with FHP (ClinicalTrials.gov:NCT02958917). Study participants must have fibrotic abnormalities involving ≥5% of the lung parenchyma on high-resolution computed tomography scan, forced vital capacity (FVC) ≥40% and diffusing capacity of the lung for carbon monoxide ≥30% of predicted values. Study participants will be randomised in a 2:1 ratio to receive pirfenidone 2403 mg·day−1or placebo. The primary efficacy end-point is the mean change in FVC % predicted from baseline to week 52. A number of secondary end-points have been chosen to evaluate the safety and efficacy in different domains.

16 October 2023 in Chest
Verified
Journal Article
Closed access
MNMelissa L. New
Melissa L. New
TATimothy Amass
Timothy Amass
ANAnna Neumeier
Anna Neumeier
NJNicholas M. Jacobson
Nicholas M. Jacobson
THTristan J. Huie
Tristan J. Huie


1 May 2023
Verified
Conference Paper
Closed access
MKM. Koslow
M. Koslow
DBD. Baraghoshi
D. Baraghoshi
MSM. Strand
M. Strand
JSJ. Solomon
J. Solomon
JSJ.J. Swigris
J.J. Swigris
SHS.M. Humphries
S.M. Humphries